Time | Subject | Room |
---|---|---|
8.30-10.00 |
MagSort workshop
• (Pre-Registration required) |
HLA Lab at 3rd floor, National Blood Centre Thai Red Cross Society |
10.00-10.20 | Break | Chumphot 1-2 Lecture Hall at 9th floor, National Blood Centre Thai Red Cross Society (120 seats) |
10.20-10.30 | Welcome | |
10.30-12.30 |
Pre-Transplant Session:
• Investigating complex antibody patterns using Single Antigen with MagSort • Case Study Presentations |
|
12.30-13.00 | Understanding Epitopes and making better decisions with HLA MatchMaker | |
13.00-13.45 | Lunch | |
13.45-15.45 |
Post-Transplant Session:
• Non-invasive biomarker monitoring using Cell Free DNA • Case Study Presentations |
|
15.45-16.00 | Break | |
16.00-17.30 |
Cell Free DNA workshop
• (Pre-registration required) |
HLA Lab at 3rd floor, National Blood Centre Thai Red Cross Society |
Time | Subject | Room | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
7.00-8.30 | Registration Open | |||||||||
8.15-8.30 | Opening Ceremony | |||||||||
Program supported by Thailand Hub of Talents in Cancer Immunotherapy, (TTCI) |
||||||||||
8.30-10.00 |
Plenary Session 1: Cellular Immunotherapy I
• Role of HSCT vs CAR T cells in Hematologic Malignancy
• Challenges in delivering cellular therapies for transplant recipients and cancer
patients
• mRNA-based T cell engineering for treatment of virus-related cancer and virus
infection |
|||||||||
10.00-10.30 | Coffee Break with Poster Session I | |||||||||
10.30-12.00 |
Plenary Session 2: Cellular Immunotherapy II
• Clinical Application of Mesenchymal Stem Cells: Current Trends and Future
Directions
• T cell receptors and MHC diversity in risk, prognosis, and therapy for gliomas
• Novel pans solid tumor CAR T cells and first in human trial in DIPG |
|||||||||
12.00-13.00 | Lunch | |||||||||
13.00-13.30 |
Sponsor Session I (Care Dx)
• Advancements in HLA loci and Permissive vs. Non-permissive Mismatches |
|||||||||
13.30-14.00 |
Sponsor Session II (Gen Dx)
• Revolutionizing Rapid High Resolution HLA Typing with NGS-Turbo® and NGS-Pronto® using Oxford Nanopore Technologies sequencing |
|||||||||
14.00-14.30 |
Short Oral Presentation I
• Anti-TROP2 CAR-T cells secreting anti-NECTIN2 scFv effectively kill high TROP2 and NECTIN2 breast cancer cells
• HLA-E triggers carcinogenesis in cervix
• Workup and validation of high throughput method for HLA high resolution allelic genotyping, ABO typing and CMV IgG status |
|||||||||
14.30-16.00 | Coffee Break with Poster Session I | |||||||||
14.00-16.30 |
Concurrent Workshop I (Hillgene/BKGI)
|
1201 | ||||||||
18.00-21.00 |
Welcome Reception (Mandarin Hotel, Managed by Center Point) |
Time | Subject | Room | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
8.30-10.00 |
Plenary Session 3: Haematopoietic Stem Cell Transplantation
• HSCT: An update
• Saving Lives Across Borders: The Asia-Pacific Unrelated Stem Cell Donor Registry
Experience |
|||||||||||
10.00-10.30 | Coffee Break with Poster Session II | |||||||||||
10.30-12.00 |
Plenary Session 4: HLA Genomics and Clinical Relevance
• HLA in Diseases Susceptibility and Personalized Medicine
• Clinical implementation of HLA long-read sequencing
• HLA Typing and Beyond with Nanopore Sequencing
• Beyond Traditional HLA Typing: NGS and HLA Imputation for Comprehensive Analysis of
HLA Alleles in Thai SLE Patients |
|||||||||||
12.00-13.00 | Lunch | |||||||||||
13.00-13.30 |
Sponsor Session III (Thermo Fisher):
Development and Validation of a High-Throughput Method for HLA High-Resolution Allelic Genotyping, ABO Typing, and CMV IgG Status Detection |
|||||||||||
13.30-14.00 |
Sponsor Session IV (TBG):
HLA Typing using Nanopore with Automation |
|||||||||||
14.00-14.30 |
Short Oral Session II
• HLA Diversity & DSA in Australian Donors
• Lnc RNAs may predict allograft rejection
• Characterisation of the Human Blood Group using third-generation sequencing |
|||||||||||
14.30-16.00 | Coffee Break with Poster Session II | |||||||||||
14.00-16.30 |
Concurrent Workshop II (Werfen)
• Werfen HLA Innovation Station
|
1201 | ||||||||||
18.00-21.00 | Gala Dinner (Councilor and Speaker Plus Guest with ticket) |
Time | Subject | Room |
---|---|---|
8.30-10.00 |
Plenary Session 5: Solid Organ Transplantation I
• Implementation of Virtual Crossmatching in Australia: the laboratory experience
• Determining compatibility in Solid Organ Transplantation – Challenges and
Opportunities
• Non-HLA antibodies in solid organ transplant |
|
10.00-10.30 | Coffee Break with Poster Session III | |
10.30-12.00 |
Interactive Session
• Case Studies for Complex Patients |
|
12.00-13.00 | Lunch | |
13.00-13.30 |
Special Lecture by the ASHI President
• Expanding Access to Transplantation: Utilization of A2 Kidneys for O and B
Recipients |
|
13.30-14.00 |
Sponsor Session V (Thermo Fisher):
Improving the Efficiency and Reliability of Post-Transplantation Monitoring and Prognosis with Donor-Derived Cell-Free DNA (dd-cfDNA) |
|
14.00-14.30 |
Short Oral Session III
• Identification of Human Leukocyte Antigen mismatches from an in-situ renal allograft biopsy in a patient re-entering the kidney transplant waitlist
• Discrepancy in Deceased Donor Typing
• Imlifidase desensitization: lab outlooks |
|
14.30-15.00 | Coffee Break with Poster Session III | |
15.00-16.00 |
Plenary Session 6: Solid Organ Transplantation II
• Management of Highly sensitized kidney transplant recipients |
|
16.00-16.15 | Concluding Remark and Closing |